Ind-Swift Laboratories Completes Preferential Issue Proceeds Utilization in Q2FY27
Ind-Swift Laboratories Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 8:17 pm
Ind-Swift Laboratories Completes Preferential Issue Proceeds Utilization in Q2FY27 Ind-Swift Laboratories fully utilized its preferential issue proceeds as of 30th Sep'26, concluding with a final deployment of Rs. 3.77 crore in Q2FY27 toward business expansion. Total funds raised and utilized reached Rs. 255.61 crore out of the targeted Rs. 314.60 crore, as 65 lakh warrants lapsed due to non-conversion by Saral Incorporated VCC Sub Fund 1, causing a Rs. 58.99 crore shortfall. The company confirmed that this shortfall will be funded via internal accruals, with unutilized issue proceeds standing at zero.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. 路 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. 路 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 路 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants 路 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... 路 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 路 30 Oct 2026
- Please refer attached pdf 路 30 Oct 2026
- Please refer attached pdf 路 30 Oct 2026
